---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004809"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:25:53.570095+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anika's Hyalofast Phase III misses co-primary endpoints; plans PMA filing by end of 2025

## Summary
- Hyalofast missed pre-specified co-primary endpoints (percent change in KOOS Pain and IKDC function vs microfracture) on statistical significance.
- Statistically significant improvements on secondary endpoints: KOOS Sports & Recreation, Quality of Life, and Total KOOS.
- Safety profile comparable to microfracture; company plans to file final PMA module in H2 2025.
- Over 35,000 patients treated outside U.S. since 2009; independent studies support safety and efficacy.
- Study impacted by higher dropout in microfracture arm and COVID-related missed visits, reducing evaluable sample size.

## SEC filing metadata
- accession: 0001171843-25-004809
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184325004809/0001171843-25-004809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184325004809/f8k_072925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004809
- JSON: https://secwatch.observer/filing/0001171843-25-004809.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.